Telomir Pharmaceuticals' Telomir-1 Shows Potential Against Leukemia

Telomir Pharmaceuticals, Inc. announced promising in vitro results of their compound Telomir-1 in killing aggressive human leukemia cells. Conducted on HL60 cells, the study illustrates Telomir-1's ability to produce a dose-dependent reduction in viable leukemia cells.

Leukemia poses persistent treatment challenges, including high relapse rates, resistance to existing therapies, and limited options for frail patients. Despite advances, these difficulties underscore the importance of exploring novel therapeutic approaches such as Telomir-1.

Leukemia cells heavily depend on iron and epigenetic silencing for survival. Telomir-1 modulates intracellular iron levels and influences epigenetic pathways, crucial in leukemia cell viability. These findings reinforce Telomir-1's role in leukemia and expand its oncology profile into blood cancers.